Roche's Global Access Program, an initiative that seeks to eradicate the HIV/AIDS epidemic, will include the company's Cobas HIV-1/HIV-2 nucleic acid test on the fully automated Cobas 6800/8800 systems. The initiative seeks to achieve by 2020 the UNAIDS 90:90:90 targets, that is, to have 90% of patients with HIV become aware of their HIV status, 90% of these patients to receive antiretroviral therapy and 90% of antiretroviral therapy recipients to have durable viral suppression.
Roche's HIV-1/HIV-2 test added to Global Access Program
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.